In preparing this update, the committee was guided by the following principles:
(1) Changes in recommendations and levels of evidence were made either because of new randomized trials or because of the accumulation of new clinical evidence and the development of clinical consensus. ( 2) The committee is cognizant of the healthcare, logistic, and financial implications of recent trials and factored in these considerations in arriving at the class level of certain recommendations. (3) Minor wording changes were made to render some recommendations more precise. (4) The committee wishes to re-emphasize that the recommendations in the guideline apply to most patients but may require modification by existing situations that only the primary treating physician can evaluate properly. (5) All of the listed recommendations for implantation of a device presume the absence of inciting causes that may be eliminated without detriment to the patient (eg, nonessential drug therapy). (6) The committee endeavored to maintain consistency of recommendations in this and other previously published guidelines. In the section on atrioventricular (AV) block associated with acute myocardial infarction (AMI), the recommendations follow closely those in the ACC/AHA Guideline for the Management of Patients With Acute Myocardial Infarction. 1 However, given the rapid evolution of pacemaker/ICD science, it has not always been possible to maintain consistency with other guidelines. An example of such a discrepancy can be found in Section I-H, in which the recommendation for biventricular pacing in selected patients with heart failure has been listed under Class IIa, whereas in the ACC/AHA Guideline for the Evaluation and Management of Chronic Heart Failure in the Adult, 2 biventricular pacing is cited as an investigational procedure.
The ACC/AHA classifications I, II, and III are used to summarize indications as follows: Class I: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.
Class II:
Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
IIb: Usefulness/efficacy is less well established by evidence/opinion.
Class III:
Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.
The weight of the evidence was ranked highest (A) if the data were derived from multiple randomized clinical trials that involved large numbers of patients and intermediate (B) if the data were derived from a limited number of randomized trials that involved small numbers of patients or from careful analyses of nonrandomized studies or observational registries. A lower rank (C) was given when expert consensus was the primary basis for the recommendation.
Recommendation 2002 New or Revised Recommendations Comments SECTION I-A: PACING FOR ACQUIRED ATRIOVENTRICULAR BLOCK IN ADULTS

Recommendations for Permanent Pacing in Acquired Atrioventricular Block in Adults
Class I Class I Class I
1. Third-degree AV block at any anatomic level, associated with any one of the following conditions:
a. Bradycardia with symptoms presumed to be due to AV block. modification (6,7) .
e. Postoperative AV block that is not
The changes emphasize the importance of the site of the block and introduce "advanced second-degree AV block" as a class I indication. This recommendation is based on several observational studies and is supported by a wealth of clinical experience. The narrative portion of this section also emphasizes that the site of origin of the escape rhythm in cases of advanced AV block is as important (or more important) than the escape rate itself.
In recommendation 1a, heart failure is specifically introduced as a major symptom that merits consideration when dealing with AV block-induced bradycardia.
In recommendation 1e, "cardiac surgery" was added to specifically define the situation(s) in which this recommendation applies.
Recommendation 1f has been amplified to indicate that pacing therapy is recommended in patients with neuromuscular diseases and expected to resolve after cardiac surgery. Addition of hypoxia occurring during periods of sleep apnea as a cause of transient AV block that is unlikely to recur once sleep apnea syndrome has been treated.
SECTION I-B: PACING FOR CHRONIC BIFASCICULAR AND TRIFASCICULAR BLOCK
Recommendations for Permanent Pacing in Chronic Bifascicular and Trifascicular Block
Class I
Class I Class I (27) (28) (29) (30) (31) (32) (33) No change 2. Type II second-degree AV block. (Level of Evidence: B) (34) (35) (36) No change
Intermittent third-degree AV block. (Level of Evidence: B)
Alternating bundle-branch block. (Level of Evidence: C) (37)
New Class I recommendation that adds alternating bundle branch block to the manifestations of fascicular block that indicate pacing therapy. This recommendation was not explicitly stated in the previous version.
Class IIa
Class IIa Class IIa 1. Sinus node dysfunction with documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms. In some patients, bradycardia is iatrogenic and will occur as a consequence of essential long-term drug therapy of a type and dose for which there are no acceptable alternatives. The change of awake heart rate from 30 to 40 bpm was made on the basis of clinical experience and provides the clinician more flexibility to consider pacing in patients with suspected sinus node dysfunction, in whom a firm diagnosis cannot be made.
Class III
Class III Class III
1. Sinus node dysfunction in asymptomatic patients, including those in whom substantial sinus bradycardia (heart rate less than 40 bpm) is a consequence of long-term drug treatment.
No change 2. Sinus node dysfunction in patients with symptoms suggestive of bradycardia that are clearly documented as not associated with a slow heart rate.
No change 3. Sinus node dysfunction with symptomatic bradycardia due to nonessential drug therapy.
No change
SECTION I-E: PREVENTION AND TERMINATION OF TACHYARRHYTHMIAS BY PACING Recommendations for Permanent Pacemakers That Automatically Detect and Pace to Terminate Tachycardias
Class I
Class I Class I
1. Symptomatic recurrent supraventricular tachycardia that is reproducibly terminated by pacing after drugs and catheter ablation fail to control the arrhythmia or produce intolerable side effects.
(Level of Evidence: C)
This recommendation was downgraded from Class I to Class IIa. Committee consensus was that it is highly unlikely that treatment with drugs and/or ablation therapy would fail to control supraventricular tachycardia (SVT) (see below). The rewording of this previously Class I recommendation is intended to convey that ablation and/or drugs are effective therapies for SVT, and it is unlikely that pacing therapy will be required.
Class IIb
Class IIb Class IIb This recommendation was revised and the level of evidence upgraded to "B" to reflect the available information. Several studies suggest that in some patients with recurrent atrial fibrillation and coexisting sinus node dysfunction, atrial-based pacing reduces the recurrence rate of this arrhythmia.
Class III
1. Frequent or complex ventricular ectopic activity without sustained VT in the absence of the long-QT syndrome.
No change 2. Long-QT syndrome due to reversible causes.
Torsade de Pointes VT due to reversible causes.
Wording change because the arrhythmia is the Torsade de Pointes VT and not the long-QT syndrome. Deleted from this section and more appropriately placed in the Sinus Node Dysfunction section as Recommendation #2, Class IIa.
Significantly symptomatic and recurrent neurocardiogenic syncope associated with bradycardia documented spontaneously or at the time of tilt-table testing. (Level of Evidence: B) (84-87)
This recommendation was added to reflect the results of trials that have demonstrated that pacing therapy is effective in cases of vasovagal syncope associated with episodes of spontaneous or provoked bradycardia. The level of evidence was set to "B" to reflect published trials. This becomes #2.
Situational vasovagal syncope in which avoidance behavior is effective. (Level of Evidence: C)
This becomes #3.
SECTION I-G: PACING IN CHILDREN, ADOLESCENTS, AND PATIENTS WITH CONGENITAL HEART DISEASE
Recommendations for Permanent Pacing in Children, Adolescents, and Patients With Congenital Heart Disease
Class I
1. Advanced second-or third-degree AV block associated with symptomatic bradycardia, congestive heart failure, or low cardiac output. (Level of Evidence: C)
Advanced second-or third-degree AV block associated with symptomatic bradycardia, ventricular dysfunction, or low cardiac output. (Level of Evidence: C)
This recommendation was reworded, substituting "ventricular dysfunction" for "congestive heart failure" to reflect accumulating clinical experience that ventricular dysfunction adversely affects the prognosis of patients with congenital third-degree AV block even in the absence of overt heart failure. Reworded recommendation to specify that AV block that persists for more than 7 days after cardiac surgery is unlikely to resolve and is best treated with the implantation of a pacemaker. The change was made because of accumulating clinical experience and published studies demonstrating adverse prognosis in such patients who did not receive a permanent pacemaker for rate support. Rewording of this recommendation to include symptoms due to chronotropic incompetence and abrupt pauses in ventricular rate in young patients with third-degree AV block after the first year of life. These events have been found to affect prognosis in patients with asymptomatic congenital third-degree AV block. The resting heart rate was changed from 35 to 40 bpm on the basis of clinical experience and expert consensus.
Patients with congenital heart disease and impaired hemodynamics due to sinus bradycardia or loss of AV synchrony. (Level of Evidence: C)
New recommendation for pacing in children with impaired hemodynamics as a result of sinus bradycardia or loss of AV synchrony. Clinical experience has accumulated that indicates that children with congenital heart disease and hemodynamic impairment as a result of these conditions have unfavorable prognosis if not paced. Modification of this recommendation to include "young adults" with congenital third-degree AV block by clinical consensus.
Class
3. Asymptomatic sinus bradycardia in the adolescent with congenital heart disease with resting heart rate less than 35 bpm or pauses in ventricular rate more than 3 seconds. (Level of Evidence: C) 3. Asymptomatic sinus bradycardia in the adolescent with congenital heart disease with resting heart rate less than 40 bpm or pauses in ventricular rate more than 3 seconds. (Level of Evidence: C)
Change of resting heart rate from 35 to 40 bpm as a result of clinical experience and expert consensus. New Class IIb recommendation for pacing in children and adolescents with a neuromuscular disease and any degree of AV block. This is similar to the recommendation for pacing in this situation for adults (Section I-A). Modification of this recommendation to clarify that pacing therapy is not indicated in symptomatic ischemic cardiomyopathy when the patient can be treated with revascularization therapy. This recommendation for ICD implantation was modified with the addition of the requirement for structural heart disease to be present. This change was made because ICD therapy is most efficacious in patients with impaired LV performance. Conversely, VT arising in structurally normal hearts can usually be treated pharmacologically or with catheter ablation.
3. Syncope of undetermined origin with clinically relevant, hemodynamically significant sustained VT or VF induced at electrophysiological study when drug therapy is ineffective, not tolerated, or not preferred. : A) (141-143) No substantive change. Level of evidence raised from "B" to "A" as a result of newly published studies. New recommendation for implantation of an ICD prophylactically in the defined population. This recommendation is promulgated as a result of a randomized trial that demonstrated a 5.6% absolute risk reduction and a 31% relative risk reduction for death in the patient group receiving an ICD. The committee consensus was that further risk stratification of the referenced population might better define the benefit of an ICD in such patients. The reader should review the discussion regarding this recommendation in the full-text guideline on the ACC, AHA, and NASPE web sites.
Spontaneous sustained VT in patients
Class IIb
Class IIb Class IIb New recommendation for ICD implantation in patients with the Brugada syndrome and syncope or family history of sudden cardiac death. Several reports suggest that ICD therapy in patients with this syndrome is effective in preventing sudden death. Changed to address the issue of many patients with structural heart disease who experience cardiac arrest in the setting of abnormal electrolytes. Such patients may still be at risk for recurrent arrhythmic events and may still benefit from ICD therapy. 
